Catalyst

Slingshot members are tracking this event:

Merck (MRK) Expects to File NDA for DPP-4 Inhibitor Omarigliptin in Treatment of Type 2 Diabetes by End of 2016 - Cancelled

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRK

100%
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda, Dpp-4 Inhibitor, Omarigliptin, Type 2 Diabetes